Abstract
Introduction
The translocation t(12;21)(p13;q22) generating ETV6-RUNX1 (TEL-AML1) gene fusion is a consistent genetic abnormality in 25% of childhood B cell precursor ALL. 1 
It typically occurs in young patients and is only occasionally detected in adolescents and
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From young adults. 2 Guthrie card analysis and twin studies have previously shown that the ETV6-RUNX1 fusion gene frequently originates before birth, probably as an initiating lesion. [3] [4] [5] Pre-leukemic clones with ETV6-RUNX1 are generated pre-natally at a rate considerably in excess of clinical ALL. 6 This, plus the modest concordance of ALL in monozygotic twins (10-15%), suggest that additional, post-natal mutations are necessary for progression to overt malignancy. 4 Modeling studies with both murine 7 or human cells 8 support this contention. Cytogenetic analyses have identified secondary chromosomal abnormalities associated with ETV6-RUNX1 + ALL of which deletion of the non-rearranged ETV6 allele appears the most frequent (~70%). 9 This ALL subtype generally has a favorable prognosis. 10 Relapses when they do occur are usually in patients off treatment. 11 These may occur several years after cessation of treatment [12] [13] [14] and occasionally after 10 -20 years. 15 Clonotypic Ig/TCR markers indicate very late relapsing ALL are clonally derived from the initially presenting clones. 16 A striking feature of late relapsing cases of ALL is that they are chemosensitive with durable term remissions possible. 17, 18 This implies that their initial survival and re-emergence is related to properties other then mutation based drug resistance. Comparison of the genomic boundaries (by microsatellite markers) of ETV6 deletions at diagnosis and relapse has previously shown that these differ in some but not all cases. 19, 20 One plausible interpretation of this finding is that the relapse clone can derive from a minor clone present at diagnosis. This view is endorsed by IgH clonotypic markers where the dominant rearrangement observed at relapse is detectable by PCR as a minor clone at diagnosis. 13, [19] [20] [21] [22] [23] The nature of such minor clones is unclear from such studies but one
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From suggestion was that they might represent persistent pre-leukemic stem cells 8 with ETV6-RUNX1 but lacking both ETV6 deletion and all other secondary genetic changes. 19, 20 Recent developments in whole genome scanning provide a greater depth of interrogation of clonal relationships. Genomic analyses using high density SNP arrays have recently
shown an average of ~6 chromosomal copy number alterations (CNA) in childhood ALL with ETV6-RUNX1 fusion gene. 21 Three recent studies have used high density CNA analysis to try and elucidate the molecular mechanism of disease recurrence in childhood ALL. These 3 studies demonstrated an increase in CNA between presentation and relapse, with B cell development and cell cycle regulation pathways most often affected. 22, 24, 25 In the majority of cases the presenting and relapse clones contained some identical CNA, suggesting a shared clonal origin. This was confirmed by back-tracking PCR some of the genetic lesions originally identified at relapse by SNP analysis. In the majority of cases the relapse "specific" lesion was present at low level at presentation in a minor subclone. 22 The authors of this study equated minor subclones to ancestral clones in a linear clonal succession model. 
Materials and Methods

Patients
Twenty-one patients with relapsed ETV6-RUNX1-positive childhood acute lymphoblastic leukemia were studied. (See Table S1 for patient characteristics) The samples were selected based on availability of DNA or viable cells at initial presentation (P), remission (Rem), and relapse (R) with blasts purity of at least 75% before extraction of DNA. The median age at diagnosis was 4.5 years (range, 1.93 -15.8 years). Time to first relapse from diagnosis was < 2 years (i.e. on treatment) to 9 years 11 months. Five out of 14 patients with data available had a white cell count > 20 x 10 9 /L. At initial presentation the bone marrow was the only site involved in all patients, whereas at relapse the bone 
Genome mapping analysis
Mapping analysis was performed using 500 ng of tumor and germ-line DNA from each patient. DNA was prepared according to manufacturer's instructions using the GeneChip mapping 500K assay protocol for hybridization to GeneChip Mapping 250K Nsp and Sty arrays (Affymetrix, Santa Clara, CA). Briefly, genomic DNA was digested in parallel with restriction endonucleases NspI and StyI, ligated to an adaptor, and subjected to polymerase chain reaction (PCR) amplification with adaptor-specific primers. The PCR products were digested with DNaseI and labeled with a biotinylated nucleotide analog.
The labeled DNA fragments were hybridized to the microarray, stained by streptavidinphycoerythrin conjugates, and washed using the Affymetrix Fluidics Station 450 and then scanned with a GeneChip scanner 3000 7G. The CEL files are available for download on http://www.icr.ac.uk/array/array.html.
Copy number and LOH analysis
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From SNP genotypes were obtained using Affymetrix GCOS software (version 1.4) to obtain raw feature intensity and Affymetrix GTYPE software (version 4.0) using the BRLMM to derive SNP genotypes. (See Table S2 for the 250K Sty / Nsp call rates) Samples were analyzed using CNAG 3.0 (http://plaza.umin.ac.jp/genome/) using paired tumor (test) samples with the self-reference control (reference) samples to determine copy number and LOH caused by imbalance. 26 The position of regions of LOH and gain were identified using the University of California Santa Cruz (UCSC) Genome Browser, May 27, 28 The remission samples were assigned a copy number of 2 and were used as a reference set to calculate copy number in tumor samples. Median smoothing with a window size of 5 was used to infer copy number along each chromosome. Loss of heterozygosity analysis was done with dChip using a Hidden Markov Model to infer the probability of loss of heterozygosity based on the paired control/tumor samples, using an average heterozygosity rate of 0.33.
Quantitative genomic PCR
The genomic copy number of the gene CDKN2A was confirmed using Taqman RealTime PCR (RQ-PCR). The Taqman probe and primers were designed using Primer Express version 3.0 (Applied Biosystems, Foster City, CA). The Taqman probes were labeled with FAM (5') and BHQ-1 (3'). The PCR reactions were performed in triplicate on the ABI 7900 PCR machine (Applied Biosystems) as per manufacturers' protocol.
The primer sequence used was: CDKN2A F, 5'-GACTGCGGAGCAATGAAGACT-3'; Table S3 
Cloning and backtracking of ETV6-RUNX1 genomic breakpoint fusion sequence.
Amplification of the genomic breakpoint fusion sequences for ETV6-RUNX1 at relapse was performed by long-range PCR using conditions and primers previously described. 29 The breakpoint sequence was obtained through restriction analysis by primer walking and sequencing ( Figure S8 ). Patient-specific primers for amplification of fusion breakpoints were designed so that PCR yielded a product of 130 to 300 base-pairs. DNA from presentation material was then amplified using these primers, and resulting products were sequenced to confirm identity with ETV6-RUNX1 intronic fusion in relapse samples (UPN 15). In 2 cases (UPN 14, 19) backtracking analysis was performed using the sequence of the fusion gene isolated at relapse. For each patient fusion breakpoint specific primers and real-time probe were designed. A dilutional series was made using DNA from relapse diagnosis and DNA pooled from mononuclear cells from 10 healthy
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Results
Recurrent copy number alterations in ETV6-RUNX1-positive ALL
We performed genome-wide analysis of copy number alterations (CNA) and loss of heterozygosity (LOH) on matched diagnostic and relapse bone marrow samples from 21 pediatric patients with precursor B cell acute lymphoblastic leukemia carrying an ETV6-RUNX1 fusion gene (t(12;21)(p12;q22)). (See Table S1 for patient characteristics) DNA copy number and LOH were obtained using the Affymetrix 500K arrays. These arrays interrogate around 500,000 loci. The average distance between single nucleotide polymorphisms (SNPs) is 5.8 kilo bases (kb).
A total of 159 CNA at diagnosis and 231 at relapse were identified (excluding physiological copy number alterations at the TCR and/or Ig loci) with a mean of 7.57 (range 0 -17) CNA per sample at initial presentation. (Table 1 ) (See Table S4 for a detailed overview of all CNA detected) Deletions outnumbered gains by approximately 6.95:1. Eighteen recurrent alterations were found in at least 2 diagnostic samples in this series. The most frequently recurring alterations at presentation were deletion of ETV6 (n=15), CDKN2A (n=4), CDKN2B (n=3), 6q16.2-3 (n=4), FHIT (n=4), and IL3RA/CSF2RA (n=5). The most frequently gained regions were 21q22.11-q22.12 (n=5), Xq26.2-q28 (n=5) and 12p13.33-p13.31 (n=2). At diagnosis, 48% of samples demonstrated one or more deletions in B cell development regulators; FHIT (n=4), BTG (n=3), RAG1/2 (n=2), CD200/BTLA (n=2), EBF1 (n=2), PAX5 (n=2), IKZF1 (n=1), and TCF3 (n=1).
Next we classified gene alterations as probable 'driver' or 'passenger' mutations. We defined 'driver' mutations as genes that are mutated on a recurrent basis in leukemia and/or are likely to be involved in leukemogenesis. 'Passenger' mutations are defined as non-recurrent and/or have no known or predicted role in leukemogenesis at present. The caveat of this approach is the potentially incorrect labeling of 'drivers' as 'passengers' due to lack of functional studies. Of the 7.36 (mean) CNA detected at presentation, 3.76 were classified as potential 'drivers' on the basis of recurrence in this or prior series of cases. 21, 22, [30] [31] [32] ( Table 1) At relapse the mean number of CNA per sample increased to 11.0 (range 0 -21), 4.86 being potential 'drivers'. (Table 1) No new recurrent genomic alterations were identified compared with diagnosis, but the frequency of particular CNA changed, as shown in Table 2 . At relapse 57% of samples showed deletions in B cell development regulator genes.
Next we compared the evolution of individual gene copy number alterations between presentation and relapse within each patient. Three patterns were established; (i) copy number alterations at presentation were lost at relapse, (ii) new alterations were gained at relapse, or (iii) an alteration persisted from presentation to relapse. More detailed analysis of 'driver' mutation evolution identifies a change in the pattern of 'driver' mutations between presentation and relapse in the majority of patients. In the 21 presentation samples a total of 20 copy number gains were detected. Twelve (60%) of these genomic gains persisted in the relapse samples. (Table 3 ) Of the 139 copy number losses at presentation, 98 (71%) remained detectable at relapse. Overall of 52 'driver' mutations persisting between presentation and relapse, 49 (94.2%) had identical chromosomal breakpoints at both time points, with the level of resolution determined by 500K SNP array analysis. In 14 patients at least one identical copy number change in a 'driver' mutation was present at both presentation and relapse. (See Table S5 for evolution of 'driver' mutations present at presentation and relapse) Of the remaining 7 patients, 6 (UPN 6, 7, 11, 14, 25, 27) shared at least one TCR and/or Ig rearrangement (confirmed by PCR and sequencing for UPN 6 and 11) between presentation and relapse.
No rearrangement data were available for 1 patient (UPN 19) at initial presentation, but for this patient we have demonstrated identical fusion breakpoint sequences at presentation and relapse. (See Table S6 for Ig and TCR rearrangement analyses at presentation and relapse) ( Figure S8 for genomic breakpoint sequences) In 16 out of 21 relapsed patients a total of 9 new copy number gains and 41 deletions in 'driver' loci appeared at relapse. At relapse the newly acquired gains were distributed on 4 chromosomal regions, namely 21q22.1-22.12 (including RUNX1) (n=3), part or whole of chromosome 16 (n=3), Xq26.2-28 (n=2) and 10p (n=1). The gene loci newly deleted at relapse were CDKN2A/B (n=7; hemizygous (n=5), homozygous n=2)), 6q16.2-3 (n=4),
'driver' mutations were observed at relapse in 5 patients ( UPN 7, 9, 13, 14, 27) Whilst this is a pragmatic scheme, it makes implicit assumptions about sub-clonal heterogeneity and ancestral relationships at presentation which are currently uncertain.
Clonal origins of relapse versus time of relapse
We therefore selected to use a modified scheme. (Table 4 Next we considered the duration of remission in each of the classified patients and sought a potential relationship between remission duration and the clonal origin of relapse, with the realization that our patients received different therapies and outcome for ALL is protocol driven, potentially clouding interpretation of data. We used the following time cut-off points: very early relapse < 2 years, early relapse 2 -5 years, and late relapse > 5 years since initial presentation. A random distribution of relapse Types 1 -4 was observed in the very early, early and late relapse categories, as shown in Table 4 (Table S1 ).
Backtracking of relapse clone to original presentation
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In our series, patient UPN2 experienced the longest remission duration, namely 9 years and 11 months. In order to establish whether in this case the relapse clone was present as a minor subclone at initial presentation, we used Fluorescent in-situ Hybridization (FISH) to detect relapse clone specific copy number alterations in the presentation sample. The SNP array data suggested duplication of the ETV6-RUNX1 fusion gene and loss of wild type ETV6 at presentation and relapse, and hemizygous loss of 9p (including CDKN2A and PAX5) in addition to loss of the other CDKN2A allele (homozygous loss of CDKN2A) at relapse (Table S4 ). FISH analysis of the presentation and relapse sample was performed in 702 and 582 cells respectively (Table S7) (Table   S7 ) (Figure S5 and S6) .
The SNP array analysis has identified duplication of the ETV6-RUNX1 fusion gene and loss of wild type ETV6 at presentation and relapse, and hemizygous loss of 9p (including CDKN2A and PAX5) in addition to loss of the other CDKN2A allele (homozygous loss of CDKN2A) at relapse (Table S4 ). The homozygous loss of CDKN2A and hemizygous loss of PAX5 in the relapse clone could have arisen in several different ways. The FISH analysis at presentation and relapse using ETV6, RUNX1, CDKN2A or ETV6, RUNX1, PAX5 probes suggested focal loss of CDKN2A before loss of the unaffected chromosome 9p containing CDKN2A and PAX5 (Table S7 )( Figure S7 ).
Discussion
The patterns of CNA we observed at diagnosis and relapse of ETV6-RUNX1-positive ALL parallel those reported in previous studies of unselected ALL. Overall, there was an increase in the number of CNA per case in relapses. 22, 24, 25, 30 The genes or regions predominantly involved were also as previously described with the two most frequently implicated pathways being cell cycle regulation and B cell development. 21, 22, 24, [30] [31] [32] In agreement with a recent study 33 , we identified frequent gain of part or whole of chromosome 16. (Figure S1 ) This finding has occasionally been described in hematological malignancy but its significance is unclear. Another novel observation was the deletion of Plasmacytoma Variant Translocation 1 (PVT1) at 8q24 in 3 cases. ( Figure   For 
org From
S2) The significance of deletion of PVT1 in our cohort remains unclear. Pvt1 is a nonprotein coding gene located 3' of myc and this locus harbors several miRNAs. Hsa-miR-1204 is often fused to the immunoglobulin light chain in variant BL and present in MYC/PVT1 co-amplified tumors. 34 Co-amplification of MYC and PVT1 has also been identified in human astrocytomas 35 , in breast and ovarian cancer 36 and in acute myeloid leukemias and myelodysplastic syndromes.
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In 14 out of 21 cases, at least one 'driver' CNA was shared between diagnosis and relapse. Ig/TCR clonality data where available (See Table S6 , data available on 15 patients) and conservation of ETV6-RUNX1 fusion (as shown for UPN 14, 15 and 19) ( Figure S8 ), indicated that relapses originated from within the clones present at diagnosis.
A principal and novel objective of this study was to compare SNP array defined copy number alterations in relapse versus matched diagnosis samples in order to gain some insight into the clonal origins of late and very late relapse in ETV6-RUNX1-positive ALL.
Other studies have looked at this issue in childhood ALL in general or ETV6-RUNX1-positive ALL in particular 25 and have drawn the conclusion that relapses (undefined by time from diagnosis) can emerge from either major or minor sub-clones present at diagnosis. 22, 23, 38 Distinct from previous studies we focused entirely on the subset of ALL with ETV6-RUNX1 to ascertain whether the apparent origin from major or minor sub-clones was associated with time to relapse. In particular, we were interested in the biologically interesting phenomenon of very late relapse in childhood ALL. These relapses can occur intraclonally up to 20 years after initial diagnosis. 15, 16, 39 These have included ETV6-RUNX1-positive cases. A striking feature is that they are often clinically responsive rather than drug-resistant and durable second remissions and cure are possible.
One possibility we and others have previously suggested was that persistent pre-leukemic clones harboring ETV6-RUNX1 -the initiating lesion but no other genetic changes, might be the reservoir for such late relapses. 7, 8, 13, 19, 20, 40 Others have interpreted clonal origins of relapse in ALL in the context of a linear model of clonal evolution in ALL with minor sub-clones considered as ancestral to major subclones. 22, 25 Recent single cell analysis with multiple FISH probes for detecting CNA indicates rather a very complex, non-linear, branching clonal structure. 41, 42 In concordance with our previous analyses, the FISH analysis performed in patient UPN2
demonstrated genetic diversity at both presentation and relapse. At presentation we on SNP array data should therefore, we suggest, be limited to the likelihood that they are derived from either the dominant or major sub-clone at diagnosis or from a minor subclone, irrespective of sub-clonal evolutionary relationships. We devised a scheme to accommodate these possibilities, defining four types of relapses in total (Table 4) . A clear conclusion from this analysis is that, in accord with other studies, relapses can originate from either major or minor sub-clones present at diagnosis.
The size of the sub-clone at diagnosis might be anticipated to influence time to relapse, as reported in some previous studies. 38, 43 However, in this series, there was no discernable relationship between early or late relapses and origins from minor or major clones at diagnosis. The basis for this discrepancy with prior data is unclear but it might reflect particular biological properties of the ETV6-RUNX1-positive subset of ALL and/or the fact that prior studies included more on-treatment, early relapses. The latter might be more likely to be drug resistant sub-clones selected by treatment as evidenced by the low frequency of sustained second remissions in such cases. Off-treatment (>3 years past diagnosis) relapses of ETV6-RUNX1-positive ALL are usually responsive to second remission inductions suggesting that their protracted survival after initial diagnosis and therapy was based on properties other than mutation-based drug resistance. There is some evidence that such sub-clones (identified via clonotypic IgH sequences) may respond slowly to induction chemotherapy. 38 One possibility is that this reflects relative quiescence and associated drug insensitivity rather than more classical, mutation-based resistance. Sustained quiescence would explain the extraordinary length of clinical remission in some of these cases. In the absence of a clear relationship between size of relapse clone at initial presentation and time to relapse in our series, we sought potential relationships between our newly devised relapse classification, number of relapse 'driver' mutations and overall outcome. No correlation was observed between our relapse classification, relapse 'drivers' and remission duration. As a consequence we cannot recommend a monitoring scheme to identify low or high risk relapses. We did however observe that all patients with Type 4 relapses (4/4) remain in complete continuous remission, whereas only 5/15 patients with a Type 1 -3 relapse are alive and in continuous remission (Table S1 ). One possible explanation for this observation is that pre-malignant clones without CNA have a more abbreviated proliferative history and if so, will be statistically less likely to harbor drug resistance mutations. 44 Pre-leukemic clones in ALL have been detected as harboring ETV6-RUNX1 gene fusions but no other discernable genetic alterations. 4, 8 Studies with monozygotic twins with discordant ALL, neonatal blood spot scrutiny and cord blood screening all suggest that these clones exist at a low level 10 -3 to 10 -4 of B lineage cells and can persist throughout childhood. 3, 5, 8, [45] [46] [47] We previously suggested that such pre-leukemic clones, perhaps as a consequence of slow growth or quiescence, might be relatively resistant to ablation by chemotherapy, would persist during and after maintenance chemotherapy and occasionally give rise to another de novo ALL masquerading as a conventional though 'late' off-treatment relapse. 19, 20 Evidence that appeared to support this view was obtained by comparing genomic boundaries of ETV6 deletion at relapse versus diagnosis where they frequently were found to be different. This indicated that the relapse emerged from a minor sub-clone that did not harbor the ETV6 deletion that was present in most cells at diagnosis. 19, 20 The comprehensive genetic profiles made available by high resolution SNP arrays provide a more stringent assessment of this hypothesis. If persistent pre-leukemic cells (defined as ETV6-RUNX1 fusion only clones) do provide the source of off-treatment late or very late relapses, then clearly not only ETV6 but all
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From the specific CNA observed at relapse should be absent at diagnosis, either at the major or minor sub-clone level. This would correspond to our Type 4 relapses ( Table 2) . As described, we observed four such cases. Three cases relapsed between three and five years from diagnosis, and one case presented as a very late relapse. Of the very late relapses (5-9 years 11 months) only one (UPN 19, Figure S3 2 . FISH analysis of UPN 2 at presentation, using the LSI TEL/AML1 ES Dual Color translocation probe (Vysis Abbott, UK), and CDKN2A probe. The red signal represents the RUNX1 probe, green the ETV6 probe, yellow the ETV6-RUNX1 fusion gene, and purple the CDKN2A probe. This image represents 2 different leukaemic cells at presentation. The cell in the right bottom corner represents the dominant leukaemic clone (according to the SNP array data analysis), with duplicated fusion gene, loss of wild type ETV6, 2 copies of CDKN2A, one normal RUNX1 and 1 ES (extra signal) (72% of total cells analysed). In the left top corner FISH analysis identified a leukaemic cell with a constellation of signals corresponding to the dominant relapse clone, i.e. a duplicated fusion gene, loss of wild type ETV6, one normal RUNX1, 1 ES (extra signal) and complete loss of CDKN2A (0.4% of total cells analyzed). In control experiments with normal blood lymphocytes from 5 donors, using the same probe combination, this CNA pattern was not observed in any cells (<0.2%).
